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Introduction
Benign prostatic hyperplasia (BPH) is a highly preva-
lent, bothersome disorder in ageing men; symptom-
atic BPH has been reported in approximately 25% of
men over 40 years and more than 30% of men over
65 years (1). BPH can be deﬁned histologically as a
hyperplasia of the stromal and epithelial tissue of the
prostate and it can be associated with lower urinary
tract symptoms (LUTS), benign prostatic enlarge-
ment (BPE) and bladder outlet obstruction (BOO)
(2,3). Patients with BPH experience a signiﬁcant
deterioration in quality of life because of their condi-
tion, reporting changes in sleep patterns, anxiety and
embarrassment, altered mobility, changes in leisure,
daily-living and sexual activities and in satisfaction
with sexual relationships (4–6). In addition, BPH is
progressive and can lead to worsening symptoms and
the risk of serious long-term complications, such as
acute urinary retention (AUR) and BPH-related sur-
gery (7).
Traditionally, BPH treatment has focussed on
achieving short-term relief of symptoms. While this
remains a key management goal, there is a growing
awareness that the progressive nature of the condi-
tion, coupled with patient perceptions and perspec-
tives on treatment choices should inform
management decisions (6). Current drug treatment
choices for management of BPH include the com-
monly prescribed a-blockers and 5a-reductase inhib-
itors (5ARIs). The former class of drugs relaxes
smooth muscle in the bladder neck and the prostate
to provide rapid symptom relief, while the 5ARIs by
inhibiting the conversion of testosterone to dihyd-
rotestosterone (DHT) – the principal driver of pros-
tate growth – provide long-term symptom relief and
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SUMMARY
Aims: Benign prostatic hyperplasia (BPH) is a bothersome disease that can pro-
gress if left untreated. However, patient and urologist perspectives on BPH man-
agement are not fully understood. The aim of the Prostate Research on Behaviour
and Education (PROBE) Survey was to assess healthcare-seeking behaviour and
attitudes to BPH treatment in 502 BPH patients, and the beliefs and management
practices of 100 urologists, from France, Germany, Italy, Spain and the UK.
Results: The principal concerns of patients seeking medical advice were fear of
cancer, sleep disruption, discomfort or embarrassment. The majority of BPH
patients recalled receiving a digital rectal examination (61%), routine prostate-spe-
ciﬁc antigen (PSA) tests (67%) and prescription medication (72%). Eighty per cent
of 5a-reductase inhibitor (5ARI) users vs. 68% of a-blocker users were satisﬁed
with their treatment. More than half of the patients were concerned about requir-
ing surgery or developing acute urinary retention, and > 75% would prefer a drug
that provides reduction in the risk of surgery than one that provides rapid symp-
tom relief. Most urologists performed digital rectal examinations (96%) and PSA
tests (71%) on > 90% of patients presenting with BPH symptoms. Eighty-seven
per cent of urologists believe that BPH progresses, and 78% believe that 5ARIs
prevent BPH progression. However, most urologists prescribe a-blockers while few
prescribe 5ARIs. Conclusions: This study highlights discrepancies between views
and beliefs of patients and physicians regarding BPH and current practice in
Europe.
What’s known
• There is increasing recognition of the importance
of the role of the patient in clinical decision-
making and the importance of consideration of
patient perceptions and preferences in ensuring
selection of the appropriate management strategy
and treatment success.
• A recently reported US national survey indicated
that currently there are signiﬁcant differences in
the beliefs and attitudes of patients and
physicians towards benign prostatic hyperplasia
(BPH) (also known as enlarged prostate) and its
management.
What’s new
• This article provides information on the views
and beliefs of both patients and urologists
towards BPH and its management, and on
current practice, across ﬁve European countries.
• This study conﬁrms and extends the ﬁndings of
the US survey and further highlights the need for
improved communication between physicians and
patients and greater involvement of the patient
during clinical decision-making.
Linked Comment:  Hindley. Int J Clin Pract 2008; 62: 2–3.
doi: 10.1111/j.1742-1241.2007.01635.x
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gery (8–11).
Several recent surveys of patient attitudes to BPH
and its treatment have revealed that men are con-
cerned about disease progression – over 60% in one
survey worried about the future need for surgery –
and desire a drug therapy that will reduce the risks of
complications and progression (12–14). Results from
a US survey indicate signiﬁcant differences between
the views and attitudes of physicians and patients
towards BPH and a lack of awareness among patients
of the possible BPH therapies and their beneﬁts (15).
This paper describes the ﬁndings of the Prostate
Research on Behaviour and Education (PROBE) sur-
vey which was conducted in ﬁve European countries
and sought the views of BPH patients currently
receiving BPH therapy and practising urologists. The
survey aimed to identify healthcare-seeking behav-
iour patterns in patients, assess the role of the
healthcare provider in diagnosis and management,
and evaluate attitudes to symptoms, complications
and treatment of BPH.
Methods
The PROBE survey was conducted in ﬁve European
countries – France, Germany, Italy, Spain and the
UK – over the period December 2002 to February
2003. The survey consisted of two questionnaires:
one for patients with BPH who were receiving drug
treatment for their condition, and the second for
practising urologists. The patient and urologist ques-
tionnaires were executed by experienced researchers
from the healthcare consultancy companies, Double
Helix Development and Research International,
respectively, and were designed to ensure answers
were elicited without prompting.
Patient survey
Recruitment of subjects for the survey was achieved
through one of the following methods: physicians or
nurses suggested participation in the survey to
patients who met the inclusion criteria (below); or
subjects were identiﬁed from screening surveys con-
ducted on the street in which men were asked if they
met the inclusion criteria. Physicians or nurses that
recruited patients into the survey had been contacted
by telephone, informed of the nature and needs of
the survey, and were provided with details so that
the patients could contact the recruiters.
Inclusion criteria for men entering the patient sur-
vey were: age 45–80 years; history of prostate prob-
lems; and BPH or an enlarged prostate leading the
patient to consult with a physician in the past
12 months. To be eligible all subjects had to be
receiving prescription medications for their prostate
problem at the time of interview.
To ensure ﬁnasteride users were not over- or
under-represented, recruitment to the survey was
quota controlled such that 50% of respondents in
each country were taking ﬁnasteride and the results
of the survey were then weighted to reﬂect the
national populations of ﬁnasteride users (national
statistics for ﬁnasteride users were provided by
GlaxoSmithKline). All responses were included in the
analysis.
All eligible subjects took part in a 40-min,
face-to-face interview based on a structured ques-
tionnaire divided into two parts. Part-1 of the ques-
tionnaire focussed on patients’ initial experiences
relating to the diagnosis and management of BPH.
This ﬁrst part of the questionnaire involved 18
questions (some with subquestions) on topics, such
as where patients ﬁrst sought advice about their
symptoms; the nature of presenting symptoms and
the key reasons for seeking medical advice; the
impact of initial symptoms on daily function and
concerns held by patients at presentation; the pro-
cess of diagnosis and the types of tests employed by
the physician or urologist in reaching a diagnosis;
information provided to patients on BPH at initial
diagnosis; and the treatments and treatment infor-
mation provided by healthcare providers in the ini-
tial stages of management. Part-2 of the
questionnaire comprised a further nine questions
(some with subquestions) relating to patients’
awareness and understanding of treatments pre-
scribed for the management of BPH symptoms and
disease progression. This section included questions
relating to treatment outcome preferences, and was
designed to assess the views and attitudes of
patients to disease progression – speciﬁcally the
development of AUR and the need for surgery.
Urologist survey
Urologists in the ﬁve participating countries were
identiﬁed through database searches and via hospital
centres by an independent agency, Research Interna-
tional. Potential participants were approached by
telephone or the internet and invited to take part in
the survey, which was conducted by telephone inter-
view and lasted approximately 15 min. All those who
agreed to be interviewed received a stipend of
30–40 euros for their time and participation.
The urologist questionnaire comprised 23 separate
items relating to physician views on the prevalence,
diagnosis, prognosis and treatment of BPH; beliefs
about patient perceptions of BPH; the treatment of
BPH; and views on a-blockers and 5ARIs in BPH
management. Questions were generally of a multi-
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option for the interviewee to decline to answer or to
answer ‘do not know’ in most instances.
Collated data from both surveys are presented
descriptively; no statistical analyses were performed.
Results
Patient survey
A total of 502 men – 100 from each of France, Italy,
Spain and the UK and 102 from Germany – met the
inclusion criteria and provided answers to the survey
questionnaire.
Presenting symptoms and general awareness of
BPH
The majority of respondents (85%) reported that
their condition was discovered through symptoms
rather than through routine examination by their
healthcare provider. Of the 502 men surveyed, 69%
of patients reported frequent micturition, 69%
reported nocturia and 54% experienced a slower/
weaker urinary stream as key presenting symptoms
of their condition.
More than half of those surveyed (56%) stated
that they felt ‘fairly’ or ‘very’ well-informed about
health issues related to prostate problems, and in
addition to consulting with their healthcare provider,
69% of patients reported that they had talked to
their partner/spouse about their prostate problems.
Healthcare-seeking behaviour and main health
concerns
On average, patients waited 10 weeks after they
noticed symptoms before consulting their healthcare
provider. Reasons cited by patients for delaying a
consultation included a hope that the symptoms
would go away or a belief that symptoms were an
inevitable part of ageing.
The main concerns ﬁrst experienced by patients
seeking medical advice for symptoms of BPH were
the fear of cancer, disruption to sleep, discomfort
and embarrassment (Figure 1). Almost one-third of
subjects (32%) cited a fear of cancer as the reason
for seeking medical help, and those with more severe
symptoms, such as blood in urine, were more likely
to harbour this underlying concern. The country-
by-country variation in answers given by patients on
healthcare-seeking behaviour was minimal (data not
shown).
Diagnosis and monitoring
At ﬁrst consultation, 61% of patients recalled having
had a digital rectal examination (DRE), and 57% a
prostate-speciﬁc antigen (PSA) test. Almost one-third
of respondents (31%) reported that they received
their diagnosis of BPH after one visit to their health-
care provider and 51% received a BPH diagnosis
within two consultations. Sixty-seven per cent of
subjects said that they routinely had PSA tests as part
of their ongoing care.
Fear that it may be cancer
Disturbed/interrupted sleep
Discomfort
Embarrassment of symptoms
Frustration with symptoms
Impact of symptoms on work/professional life
Impact of symptoms on social activities/life
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Figure 1 Proportion of patients with concerns (severe, moderate or mild) about their initial BPH symptoms (n ¼ 502)
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When asked about the ongoing symptoms of BPH
experienced about half or more than half of the time
in the past month, 41% of patients reported a weak
urinary stream, 39% a sensation of not emptying
their bladder completely, and 31% a need to push or
strain to start urinating. A high proportion of
patients (92%) reported getting up at least once in
the night to urinate and within this group, 20% got
up once, 35% twice, 19% three times, 8% four times
and 10% ﬁve or more times in the night.
Drug treatment
Of all respondents, 72% were given a prescription
medication for BPH symptoms on their ﬁrst or sec-
ond consultation. In response to questions relating
to satisfaction with current therapy, more patients
receiving the 5ARI treatment ﬁnasteride as mono-
therapy (80%) reported being ‘fairly’ or ‘very’ satis-
ﬁed with treatment than patients on a-blocker
monotherapy (68%) (Table 1). There was variation
amongst countries: Italy had the greatest proportion
of patients (85%) who were fairly or very satisﬁed
with ﬁnasteride, while Germany had the lowest pro-
portion (60%). This difference reﬂected the differ-
ence in the proportion of patients using ﬁnasteride
in these countries.
Nearly one-ﬁfth of patients surveyed (19%) had
their prescription medication changed since original
diagnosis. The main reason cited for dis-satisfaction
with current therapy was a lack of symptom
improvement (38% of patients).
Complications associated with BPH
More than half of all respondents (n ¼ 273, 54%)
had discussed the topic of prostate-related surgery
with their healthcare provider, and 56% of these
patients reported that they were ‘fairly’ or ‘very’ con-
cerned about surgery (Figure 2). Nearly a quarter of
patients (n ¼ 117, 24%) had discussed the issue of
AUR, and 58% of these patients reported being
‘fairly’ or ‘very’ concerned about developing this
complication (Figure 2). There was little country-by-
country variation for patient concern with surgery
and AUR (data not shown).
Views on treatment preference
When asked to rate attributes of a drug treatment
for BPH on a scale of 1–8, where 1 refers to a 50%
reduction in the risk of surgery and onset of symp-
tom relief within 6 months, and 8 refers to relief
from symptoms within 2 weeks but no reduction in
the risk of surgery, the average total score was 3.0.
More than three-quarters of patients reported that
they would prefer a drug that provides a 50% reduc-
tion in the risk of needing surgery (i.e. score 1–4)
rather than a drug offering faster symptom relief
(Figure 3). There was some country-by-country
Table 1 Patient satisfaction (very, fairly, not very, not at all) with a-blocker therapy alone (A) and 5a-reductase
inhibitor therapy alone (B)
Patient opinion
Number of patients
Overall percentage
of patients UK France Germany Italy Spain Total
A
a-blocker
Not at all satisﬁed 3 0 0 0 0 3 1
Not very satisﬁed 5 5 10 6 2 28 10
Fairly satisﬁed 12 40 32 34 23 141 49
Very satisﬁed 16 17 4 4 14 55 19
Neither satisﬁed nor dis-satisﬁed 8 8 8 9 17 50 17
Do not know 3 2 4 0 2 11 4
Total 47 72 58 53 58 288 100
B
5a-reductase inhibitor
Not at all satisﬁed 0 0 0 0 0 0 0
Not very satisﬁed 1 0 1 2 0 4 6
Fairly satisﬁed 7 9 2 14 6 38 58
Very satisﬁed 5 1 1 3 4 14 22
Neither satisﬁed nor dis-satisﬁed 2 1 1 1 2 7 11
Do not know 1 1 0 0 0 2 3
Total 16 12 5 20 12 65 100
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portion of patients giving a rating of 1 was highest
in Spain (67%), lowest in the UK (23%). However,
the overall view was in favour of reducing progres-
sion to surgery and this preference held true irre-
spective of whether the respondent was currently
taking an a-blocker or a 5ARI-based therapy.
Urologist survey
A total of 100 urologists – 20 from each of the ﬁve
participating countries – took part in the survey. Of
the urologist respondents, 85% see more than 10
new patients with symptomatic BPH every working
month.
Beliefs about patient consulting behaviour
More than half of urologists (57%) considered that
> 45% of the male population over 60 years of age
are likely to suffer from BPH. Similarly, 60%
believed > 60% of the male population over 80 years
of age are likely to suffer from BPH.
In response to questions about why men with
BPH symptoms may fail to seek medical advice, 45%
of urologists stated the main reason to be that
patients consider symptoms to be an inevitable part
of ageing. Almost all urologists (91%) believed that
patients with BPH eventually consult their physician
because of bother from irritative or obstructive
symptoms.
The majority of the urologists believed that it
would be valuable (51% reported ‘very valuable’ and
40% reported ‘of some value’) to raise awareness of
BPH in the general population within their respective
countries.
Urologist assessment of BPH
The standard diagnostic assessments of a DRE and
PSA assay were performed by 96% and 71% of urol-
ogists, respectively, on more than 90% of their
patients presenting with symptoms suggestive of
BPH. However, in the UK, only 35% of urologists
performed a PSA test more than 90% of the time,
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Europe.
Views on BPH progression and complications
When assessing patients with BPH during ongoing
care, 56% of the urologists believed that a worsening
of symptoms, the need for surgery, and AUR were
all clear indicators of BPH progression. Indeed, 87%
of the urologists believed that BPH is a condition
that progresses. Yet only 58% of these same physi-
cians believed that their patients understand that
BPH can progress (Table 2). Country-by-country
variation existed. The difference between the urolo-
gists’ own opinion on whether or not BPH pro-
gresses and the urologists’ perception of the patients’
opinion on this subject was greatest in Germany;
95% vs. 50%. The proportion of urologists believe
that BPH progresses was lowest in the UK (70%).
More urologists thought patients would progress to
needing surgery than would progress to developing
AUR. Greater than half of respondents (59%)
believed that < 10% of their patients will progress to
AUR in the next 4 years, while 82% believed > 10%
of patients are likely to require prostate surgery in
the next 4 years.
BPH prescribing habits
Most urologists (63%) reported that they prescribe
drug therapy to > 70% of their patients. Of the urol-
ogists who chose drug treatment, 58% prescribe
a-blockers in > 70% of cases, while 5ARIs are used
less frequently, being chosen by 47% of urologists for
< 10% of cases (Table 3). The proportion of urolo-
gists prescribing a-blockers was highest in the UK
(75% to > 70% of patients), whilst the proportion of
urologists prescribing 5ARIs (45% to 31–70% of
patients) was highest in Italy.
Among the factors considered when choosing to
prescribe drugs were evidence of BPH progression
(important to 66% of urologists) and prostate volume
(important to 68% of urologists, although less of an
inﬂuence on French urologists) (data not shown).
When asked which drug therapies they regarded as
having potential to affect BPH progression, all Span-
ish urologists interviewed believed that 5ARIs are
most effective in this regard, when compared with
60% of UK urologists. Although there was variation
amongst countries, overall 78% believed 5ARIs inhi-
bit BPH progression, while almost half (44%)
thought that a-blockers may reduce the risk of dis-
ease progression (Table 4).
Discussion
The results of the PROBE survey conﬁrm that most
men initially consult their physician because of clas-
sic signs and symptoms of BPH related to LUTS,
such as urinary hesitancy, frequent micturition and
nocturia. There is little variation in healthcare-seek-
ing behaviour between the European countries stud-
ied. In response to such symptoms, physicians
appear to provide a rapid and thorough diagnostic
work-up and instigate early use of drug treatment
with a view to achieving fast and effective symptom
relief. However, this survey also identiﬁes that when
patients and physicians are asked to consider the
complications and progression of BPH, attitudes to
treatment of the condition may vary between the
physician and the patient. The PROBE survey indi-
cates that over three-quarters of BPH patients would
Table 2 Urologists’ opinion on whether BPH progresses (A) and on whether their patients realise that BPH progresses
(B)
Urologists’ opinion
Number of urologists
Overall percentage
of urologists UK France Germany Italy Spain
A
Urologists’ opinion on whether BPH progresses
Yes 14 19 19 17 18 87
No 0 0 1 1 0 2
Some patients 6 1 0 2 2 11
Total 20 20 20 20 20 100
B
Urologists’ opinion on whether their patients believe BPH progresses
Yes 10 10 10 13 15 58
No 7 10 5 6 5 33
Do not know/refused 3 0 5 1 0 9
Total 20 20 20 20 20 100
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tion in their risk of needing surgery in the future
over a drug treatment designed principally for symp-
tomatic relief. This is consistent with the results from
US and British surveys which have demonstrated that
patients are willing to trade immediate symptom
relief for a reduction in the risk of progression
(14,15). Indeed in the US survey, 73% of patients
with mild symptoms of BPH and 75% of patients
with moderate-to-severe symptoms rated a 50%
decrease in the risk of surgery as an essential or
important attribute for a new drug treating BPH;
symptom relief within the ﬁrst few weeks was
selected as important or essential by < 60% of
patients with symptoms of BPH (15). Thus, BPH
patients may not be as concerned about rapid symp-
tom relief as physicians have tended to believe.
The two main drug classes prescribed in daily
management of BPH are a-blockers and 5ARIs.
Both classes of drug provide symptomatic relief,
with the a-blockers recognised to provide rapid
symptom relief, and the 5ARIs known to reduce
prostate size and reduce the long-term risk of BPH
progression and its associated complications, such
Table 3 Proportion of patients for which urologists prescribe a-blockers (A) and 5a-reductase inhibitors (B)
Percentage of patients
Number of urologists
Overall percentage
of urologists UK France Germany Italy Spain
A
Urologists prescribing a-blockers
<1 0 0 0 0 0 0 0
10–30 1 0 1 0 0 2
31–50 0 1 6 0 1 8
51–70 4 7 6 9 6 32
> 70 15 12 7 11 13 58
Total 20 20 20 20 20 100
B
Urologists prescribing 5a-reductase inhibitors
<1 0 1 1 1 1 1 6 3 6 4 7
10–30 7 7 4 8 12 38
31–50 1 2 0 6 2 11
51–70 1 0 0 3 0 4
>7 0 0 0 0 0 0 0
Total 20 20 20 20 20 100
Table 4 Urologists’ opinion on whether a-blockers (A) or 5a-reductase inhibitors (B) are considered to reduce the risk
of progression
Urologists’ opinion
Number of urologists
Overall percentage
of urologists UK France Germany Italy Spain
A
a-blockers
Yes 9 9 8 11 7 44
No 7 10 12 9 13 51
Do not know 4 1 0 0 0 5
Total 20 20 20 20 20 100
B
5a-reductase inhibitors
Yes 14 16 16 12 20 78
No 4 3 3 6 0 16
Do not know 2 1 1 2 0 6
Total 20 20 20 20 20 100
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PROBE survey suggests that, while as many as 66%
of urologists profess to consider BPH progression
when selecting a treatment and view 5ARIs as the
treatment choice most likely to have an effect on
disease progression, they employ 5ARI therapy in
patient management less often than a-blockers. This
disparity in beliefs and practices is at odds with
patient preferences regarding the most important
goals of BPH therapy.
Patient concerns and healthcare-seeking behaviour
remained fairly consistent between countries. How-
ever, patient preferences with regard to BPH treat-
ment did vary: more Spanish patients – and fewer
UK patients – preferred a drug that reduces surgery
over one that reduces symptoms. Urologist practices
and beliefs also varied between countries: for exam-
ple, UK urologists performed PSA testing much less
frequently than other European countries. In addi-
tion, although overall most urologists believe that
BPH progresses, the variation between countries ran-
ged from 70% of urologists in the UK to 95% in
France and Germany. There was also some country-
by-country variation in the prescribing frequency of
a-blockers and 5ARIs, with UK urologists being the
highest prescribers of a-blockers. It seems likely that
one of the underlying factors inﬂuencing both urolo-
gist and patient responses was the national healthcare
systems. This could have been responsible for some
of the country-by-country variation.
A number of recent surveys of patients with BPH
have highlighted that patients with this condition do
experience great worry over the prospect of surgery
should their condition progress (12–15). The results
of the PROBE survey suggest that if BPH patients
were made aware of the relative beneﬁts of a-block-
ers and 5ARIs, they may prefer to take a 5ARI to
reduce their risk of surgery.
As patients become increasingly more involved in
decisions about their healthcare, surveys gauging
what matters to patients with chronic complaints in
terms of clinical outcomes and health-related quality
of life are becoming seen as more important. For
example, a survey of women with stress incontinence
(16) highlighted that more than three-quarters of
women troubled by this common form of urinary
incontinence are very bothered by their condition,
and that often physicians fail to pick up on the
aspects of urological complaints, which cause great
stress to patients in their daily lives.
The PROBE survey highlights that BPH is a condi-
tion that concerns and worries patients despite
receiving treatment. Early in the presentation,
patients worry that their symptoms may indicate an
underlying malignancy. When the disease is recogni-
sed as BPH, patients’ worry may then shift to a fear
of the need for future surgery or the development of
AUR.
This survey suffers from limitations inherent to all
surveys, including the wording and order of ques-
tions and the potential inﬂuence and bias of the
interviewer. In addition, only descriptive data are
presented; statistical comparisons were not per-
formed. However, this survey provides a valuable
insight into the views and beliefs of patients and
physicians regarding BPH and its management, and
current practices across Europe and serves to high-
light the need for further improvement in communi-
cation between physicians and patients and
consideration of patient preferences during clinical
decision-making.
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